Products
Platform
Research
Market
Learn
Compare SBI Healthcare Opportunities Fund vs DSP Healthcare Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 5.0 | 4.0 |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 1.93 | 1.91 |
NAV | ₹438.46 | ₹39.27 |
Fund Started | 04 Jun 1999 | 12 Nov 2018 |
Fund Size | ₹3933.26 Cr | ₹3074.18 Cr |
Exit Load | Exit load of 0.50% if redeemed within 15 days | Exit load of 0.50% if redeemed within 1 month. |
Risk
Very High
Very High
Rating
5.0
4.0
Min SIP Amount
₹500
₹100
Expense Ratio
1.93
1.91
NAV
₹438.46
₹39.27
Fund Started
04 Jun 1999
12 Nov 2018
Fund Size
₹3933.26 Cr
₹3074.18 Cr
Exit Load
Exit load of 0.50% if redeemed within 15 days
Exit load of 0.50% if redeemed within 1 month.
Returns
1 Year | 4.57% | -4.65% |
3 Year | 26.06% | 23.14% |
5 Year | 19.48% | 17.36% |
1 Year
4.57%
-4.65%
3 Year
26.06%
23.14%
5 Year
19.48%
17.36%
Holding Analysis
Equity | 96.36% | 97.26% |
Cash | 3.56% | 2.74% |
Equity
96.36%
97.26%
Cash
3.56%
2.74%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 10.94% |
Divi's Laboratories Ltd. | 6.36% |
Max Healthcare Institute Ltd. | 5.67% |
Cipla Ltd. | 4.59% |
Lupin Ltd. | 4.08% |
Lonza Group Ag | 4.06% |
Fortis Healthcare Ltd. | 3.70% |
Torrent Pharmaceuticals Ltd. | 3.66% |
Gland Pharma Ltd. | 3.54% |
Mankind Pharma Ltd. | 3.34% |
Name | Assets |
|---|---|
Cipla Ltd. | 8.76% |
Sun Pharmaceutical Industries Ltd. | 7.96% |
Cohance Lifesciences Ltd. | 7.90% |
Ipca Laboratories Ltd. | 7.39% |
Laurus Labs Ltd. | 6.07% |
Gland Pharma Ltd. | 5.96% |
Sai Life Sciences Ltd. | 4.77% |
Apollo Hospitals Enterprise Ltd. | 4.69% |
Globus Medical Inc | 4.45% |
Illumina Inc. (USA) | 4.40% |
Fund Manager
Name | Tanmaya Desai | Jay Kothari |
Start Date | 17 May 2024 | 07 Mar 2024 |
Name
Tanmaya Desai
Jay Kothari
Start Date
17 May 2024
07 Mar 2024
About Fund
Description | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. | The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. |
Launch Date | 04 Jun 1999 | 12 Nov 2018 |
Description
The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
Launch Date
04 Jun 1999
12 Nov 2018